FDA designates ifinatamab deruxtecan as a breakthrough therapy for extensive-stage small cell lung cancer, promising improved ...

The FDA designates iza-bren as a breakthrough therapy for advanced EGFR-mutant NSCLC, promising improved outcomes for ...

Jered Haddad transforms his cancer journey into a mission, cycling in Iceland to raise awareness and funds for multiple ...

Zev A. Wainberg, MD, discussed the significance of the AMPLIFY-201 trial, next steps for this vaccine platform, and the signs ...

Neoadjuvant immunotherapy combined with chemotherapy shows promising results in treating limited-stage small cell lung cancer ...

Pembrolizumab showed an 89% objective response rate in unresectable desmoplastic melanoma, with a 37% complete response rate.

Fertility preservation becomes crucial for reproductive-age cancer patients, emphasizing timely intervention and ...

Explore the evolving treatment landscape of chronic myeloid leukemia with asciminib, a promising new TKI showing high ...

FDA fast-tracks HLD-0915, a novel therapy for metastatic castration-resistant prostate cancer, promising rapid development ...

Discover the latest breakthroughs in oncology, including FDA approvals and innovative treatments reshaping cancer care for patients and clinicians alike.

During a live event, Misty D. Shields, MD, PhD, discussed using G-CSF and trilaciclib to mitigate chemotherapy-induced ...

New research reveals that combining talazoparib with enzalutamide significantly enhances survival rates in metastatic ...